<DOC>
	<DOCNO>NCT00234494</DOCNO>
	<brief_summary>Cisplatin important agent treatment TCC single agent response rate approximately 15 % . However , important part combination chemotherapy , MVAC initially combination gemcitabine . Single agent gemcitabine demonstrate overall response rate ( ORR ) approximately 25 % , include complete response ( CR ) , minimal toxicity patient advanced bladder cancer . Bevacizumab , murine anti-human VEGF monoclonal antibody , advanced use combination cytotoxic chemotherapy delay time disease progression patient metastatic solid tumor . This trial design assess efficacy , safety tolerability regimen patient population .</brief_summary>
	<brief_title>Cisplatin , Gemcitabine Bevacizumab Combination Metastatic Transitional Cell Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Cisplatin 70 mg/m2 Day 1 - Gemcitabine 1250 mg/m2 Day 1 8 - Bevacizumab 15 mg/kg Day 1 Review toxicity every cycle ( every 3 week ) Review radiographic response every 2 cycle ( every six week ) Progressive disease = protocol therapy Patients treat maximum 8 cycle cisplatin gemcitabine ( 24 week therapy ) . If patient progress end 24 week ( completion cisplatin gemcitabine ) , patient treat bevacizumab 15 mg/kg every three week maximum 12 month bevacizumab therapy ( since study entry ) . If time patient undue toxicity progressive disease , patient remove study follow progression survival . If patient Grade 3 4 neurotoxicity and/or creatinine rise 2.0 , cisplatin discontinue patient continue study treat gemcitabine bevacizumab dose schedule . ECOG Performance Status 0 1 Hematopoietic : - White blood cell count &gt; 3000/mm3 - Absolute neutrophil count ( ANC ) &gt; 1500 mm/3 - Platelet count &gt; 100,000/mm3 - Hemoglobin &gt; 8 g/dL ( may transfuse receive erythropoietin support maintain exceed level ) . - INR &lt; 1.5 - No full dose/therapeutic anticoagulation either low molecular weight heparin unfractionated heparin coumadin Hepatic : - Total bilirubin &lt; 1.5 mg/dL - ALT &lt; 5 time upper limit normal subject document liver metastasis ; &lt; 2.5 time upper limit normal subject without evidence liver metastasis . Renal : - Serum creatinine &lt; 1.5 mg/dL . - Urine protein : creatinine ratio &lt; 1.0 screen Cardiovascular : - No history myocardial infarction stroke within last 6 month - No uncontrolled hypertension ( blood pressure &gt; 160 systolic and/or 110 diastolic mmHg medication ) - No unstable angina , New York Heart Association ( NYHA ) Grade II great congestive heart failure - No unstable symptomatic arrhythmia require medication ( subject chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia eligible ) , clinically significant peripheral vascular disease . Pulmonary : - Not specify</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Previously untreated relapse locally advanced metastatic transitional cell carcinoma bladder . ( Patients pathology show ANY component nontransitional cell histology eligible ) . Relapsed patient may receive prior chemotherapy â‰¥ one year prior study registration part neoadjuvant adjuvant regimen must intervene therapy end treatment study entry . Measurable disease per RECIST . Prior radiation therapy , immunotherapy , cytokine , biologic vaccine therapy must great 28 day prior register protocol therapy , No known central nervous system metastasis . ( image brain require clinically indicate ) No prior organ allograft . No history disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication . No evidence bleed diathesis coagulopathy . No history serious , nonhealing wound , ulcer bone fracture No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior register protocol therapy . No prior history malignancy past 5 year exception basal cell squamous cell carcinoma skin . Other cancer low potential metastasis , situ cancer ( e.g. , Grade 1 , TA TCC ( low grade superficial bladder cancer ) , colonic polyp focus adenocarcinoma ) also enrol approval study chair . No major surgical procedure , open biopsy , significant traumatic injury le 28 day prior register protocol therapy . Patients eligible need major surgical procedure anticipate course study . Any minor surgical procedure , fine needle aspiration core biopsy must great 7 day prior register protocol therapy except procedure secure vascular access device must great 7 day prior start protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>